← Back to patent-cliff list
QBS-10072-S
Tier C — Watch / tradeQBS-10072-S
Quadriga Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LAT1
Indications (approved)：Breast cancer, Lung cancer, 脑膜肿瘤, Brain metastases, Solid tumour, Bladder cancer, Cholangiocarcinoma, Liver cancer
Regional status
US
Phase II
2022-08-16
EU
-
China
Phase II
2025-03-26
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of QBS-10072-S?
Approved indications include: Breast cancer, Lung cancer, 脑膜肿瘤, Brain metastases, Solid tumour, Bladder cancer, Cholangiocarcinoma, Liver cancer.
When does the QBS-10072-S patent expire?
No public expiry year is available for QBS-10072-S yet; this page updates once verified.
How do I get a quote for QBS-10072-S intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-05